

# Irritable bowel syndrome in adults: diagnosis and management

Clinical guideline

Published: 23 February 2008

[nice.org.uk/guidance/cg61](https://www.nice.org.uk/guidance/cg61)

## Your responsibility

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

## Contents

Introduction .....	5
Recommendations about medicines .....	6
Patient-centred care .....	7
Key priorities for implementation .....	8
1 Recommendations .....	11
1.1 Diagnosis of IBS.....	11
1.2 Clinical management of IBS.....	14
2 Research recommendations .....	18
2.1 Low-dose antidepressants .....	18
2.2 Psychological interventions .....	18
2.3 Refractory IBS.....	19
2.4 Relaxation and biofeedback.....	19
2.5 Herbal medicines .....	20
3 Other information.....	21
3.1 Scope and how this guideline was developed.....	21
3.2 Related NICE guidance.....	21
4 Committee members and NICE staff.....	23
4.1 Committee members .....	23
4.2 Clinical Guidelines Update Team.....	23
4.3 NICE project team.....	24
4.4 Declarations of interests .....	25
About this guideline .....	33
Update information.....	33
Strength of recommendations.....	34
Other versions of this guideline .....	35
Implementation .....	35
Your responsibility.....	35



This guideline is partially replaced by CG122.

This guideline is the basis of QS114 and QS134.

## Introduction

Recommendations on dietary and lifestyle advice and pharmacological therapy have been added to and updated in sections 1.2.1 and 1.2.2. The [guideline addendum](#) contains details of the methods and evidence used to update these recommendations.

Irritable bowel syndrome (IBS) is a chronic, relapsing and often life-long disorder. It is characterised by the presence of abdominal pain or discomfort, which may be associated with defaecation and/or accompanied by a change in bowel habit. Symptoms may include disordered defaecation (constipation or diarrhoea or both) and abdominal distension, usually referred to as bloating. Symptoms sometimes overlap with other gastrointestinal disorders such as non-ulcer dyspepsia or coeliac disease. People with IBS present to primary care with a wide range of symptoms, some of which they may be reluctant to disclose without sensitive questioning.

People with IBS present with varying symptom profiles, most commonly 'diarrhoea predominant', 'constipation predominant' or alternating symptom profiles. IBS most often affects people between the ages of 20 and 30 years and is twice as common in women as in men. Prevalence in the general population is estimated to be between 10% and 20%. Recent trends indicate that there is also a significant prevalence of IBS in older people. IBS diagnosis should be a consideration when an older person presents with unexplained abdominal symptoms.

Key aspects of this guideline include establishing a diagnosis; referral into secondary care only after identification of 'red flags' (symptoms and/or features that may be caused by another condition that needs investigation); providing lifestyle advice; drug and psychological interventions; and referral and follow-up. The guideline refers to NICE's [referral guidelines for suspected cancer](#) in relation to appropriate referral to secondary care.

The main aims of this guideline are to:

- provide positive diagnostic criteria for people presenting with symptoms suggestive of IBS
- provide guidance on clinical and cost-effective management of IBS in primary care

- determine clinical indications for referral to IBS services, taking into account cost effectiveness.

### *Recommendations about medicines*

The guideline will assume that prescribers will use a medicine's summary of product characteristics to inform decisions made with individual patients.

This guideline recommends some medicines for indications for which they do not have a UK marketing authorisation at the date of publication, if there is good evidence to support that use. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. The patient (or those with authority to give consent on their behalf) should provide informed consent, which should be documented. See the General Medical Council's [Good practice in prescribing and managing medicines and devices](#) for further information. Where recommendations have been made for the use of medicines outside their licensed indications ('off-label use'), these medicines are marked with a footnote in the recommendations.

## Patient-centred care

This guideline offers best practice advice on the care of adults with IBS.

Patients and healthcare professionals have rights and responsibilities as set out in the [NHS Constitution for England](#) – all NICE guidance is written to reflect these. Treatment and care should take into account individual needs and preferences. Patients should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals. Healthcare professionals should follow the [Department of Health's advice on consent](#). If someone does not have capacity to make decisions, healthcare professionals should follow the [code of practice that accompanies the Mental Capacity Act](#) and the supplementary [code of practice on deprivation of liberty safeguards](#).

NICE has produced guidance on the components of good patient experience in adult NHS services. All healthcare professionals should follow the recommendations in [Patient experience in adult NHS services](#).

## Key priorities for implementation

The following recommendations were identified as priorities for implementation in the 2008 guideline and have not been changed in the 2015 update.

### Initial assessment

- Healthcare professionals should consider assessment for IBS if the person reports having had any of the following symptoms for at least 6 months:
  - Abdominal pain or discomfort
  - Bloating
  - Change in bowel habit. [2008]
- All people presenting with possible IBS symptoms should be asked if they have any of the following 'red flag' indicators and should be referred to secondary care for further investigation if any are present:<sup>[1]</sup>
  - unintentional and unexplained weight loss
  - rectal bleeding
  - a family history of bowel or ovarian cancer
  - a change in bowel habit to looser and/or more frequent stools persisting for more than 6 weeks in a person aged over 60 years. [2008]
- All people presenting with possible IBS symptoms should be assessed and clinically examined for the following 'red flag' indicators and should be referred to secondary care for further investigation if any are present:<sup>[1]</sup>
  - anaemia
  - abdominal masses
  - rectal masses
  - inflammatory markers for inflammatory bowel disease.

Measure serum CA125 in primary care in women with symptoms that suggest ovarian cancer in line with the NICE guideline on [ovarian cancer](#).<sup>[1]</sup> [2008]



- A diagnosis of IBS should be considered only if the person has abdominal pain or discomfort that is either relieved by defaecation or associated with altered bowel frequency or stool form. This should be accompanied by at least two of the following four symptoms:
  - altered stool passage (straining, urgency, incomplete evacuation)
  - abdominal bloating (more common in women than men), distension, tension or hardness
  - symptoms made worse by eating
  - passage of mucus.

Other features such as lethargy, nausea, backache and bladder symptoms are common in people with IBS, and may be used to support the diagnosis. [2008]

### Diagnostic tests

- In people who meet the IBS diagnostic criteria, the following tests should be undertaken to exclude other diagnoses:
  - full blood count (FBC)
  - erythrocyte sedimentation rate (ESR) or plasma viscosity
  - c-reactive protein (CRP)
  - antibody testing for coeliac disease (endomysial antibodies [EMA] or tissue transglutaminase [TTG]). [2008]
- The following tests are not necessary to confirm diagnosis in people who meet the IBS diagnostic criteria:
  - ultrasound
  - rigid/flexible sigmoidoscopy
  - colonoscopy; barium enema
  - thyroid function test
  - faecal ova and parasite test
  - faecal occult blood

- hydrogen breath test (for lactose intolerance and bacterial overgrowth). [2008]

### Dietary and lifestyle advice

- People with IBS should be given information that explains the importance of self-help in effectively managing their IBS. This should include information on general lifestyle, physical activity, diet and symptom-targeted medication. [2008]
- Healthcare professionals should review the fibre intake of people with IBS, adjusting (usually reducing) it while monitoring the effect on symptoms. People with IBS should be discouraged from eating insoluble fibre (for example, bran). If an increase in dietary fibre is advised, it should be soluble fibre such as ispaghula powder or foods high in soluble fibre (for example, oats). [2008]

### Pharmacological therapy

- People with IBS should be advised how to adjust their doses of laxative or ant motility agent according to the clinical response. The dose should be titrated according to stool consistency, with the aim of achieving a soft, well-formed stool (corresponding to Bristol Stool Form Scale type 4). [2008]
- Consider tricyclic antidepressants (TCAs) as second-line treatment for people with IBS if laxatives, loperamide or antispasmodics have not helped. Start treatment at a low dose (5–10 mg equivalent of amitriptyline), taken once at night, and review regularly. Increase the dose if needed, but not usually beyond 30 mg. <sup>[3]</sup> [2015]

---

<sup>[1]</sup> See NICE's [referral guidelines for suspected cancer](#) for detailed referral criteria where cancer is suspected.

<sup>[2]</sup> This recommendation was updated in September 2012 in line with more recent guidance on the recognition and management of ovarian cancer in the NICE guideline on [ovarian cancer](#).

<sup>[3]</sup> At the time of publication (February 2015), TCAs did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Good practice in prescribing and managing medicines and devices](#) for further information.

## 1 Recommendations

The following guidance is based on the best available evidence. The [full guideline](#) gives details of the methods and the evidence used to develop the 2008 recommendations. The [guideline addendum](#) gives details of the methods and the evidence used to develop the 2015 recommendations.

The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation). See [about this guideline](#) for details.

Diagnosis and management of irritable bowel syndrome (IBS) can be frustrating, both for people presenting with IBS symptoms and for clinicians. Both parties need to understand the limitations of current knowledge about IBS and to recognise the chronic nature of the condition.

### 1.1 *Diagnosis of IBS*

Confirming a diagnosis of IBS is a crucial part of this guideline. The primary aim should be to establish the person's symptom profile, with abdominal pain or discomfort being a key symptom. It is also necessary to establish the quantity and quality of the pain or discomfort, and to identify its site (which can be anywhere in the abdomen) and whether this varies. This distinguishes IBS from cancer-related pain, which typically has a fixed site.

When establishing bowel habit, showing people the Bristol Stool Form Scale (see appendix I of the full guideline) may help them with description, particularly when determining quality and quantity of stool. People presenting with IBS symptoms commonly report incomplete evacuation/rectal hypersensitivity, as well as urgency, which is increased in diarrhoea-predominant IBS. About 20% of people experiencing faecal incontinence disclose their incontinence only if asked. People who present with symptoms of IBS should be asked open questions to establish the presence of such symptoms (for example, 'tell me about how your symptoms affect aspects of your daily life, such as leaving the house'). Healthcare professionals should be sensitive to the cultural, ethnic and communication needs of people for whom English is not a first language or who may have cognitive and/or behavioural problems or disabilities. These factors should be taken into consideration to facilitate effective consultation.

### 1.1.1 Initial assessment

1.1.1.1 Healthcare professionals should consider assessment for IBS if the person reports having had any of the following symptoms for at least 6 months:

- Abdominal pain or discomfort
- Bloating
- Change in bowel habit. [2008]

1.1.1.2 All people presenting with possible IBS symptoms should be asked if they have any of the following 'red flag' indicators and should be referred to secondary care for further investigation if any are present:<sup>[4]</sup>

- unintentional and unexplained weight loss
- rectal bleeding
- a family history of bowel or ovarian cancer
- a change in bowel habit to looser and/or more frequent stools persisting for more than 6 weeks in a person aged over 60 years. [2008]

1.1.1.3 All people presenting with possible IBS symptoms should be assessed and clinically examined for the following 'red flag' indicators and should be referred to secondary care for further investigation if any are present:<sup>[4]</sup>

- anaemia
- abdominal masses
- rectal masses
- inflammatory markers for inflammatory bowel disease.

Measure serum CA125 in primary care in women with symptoms that suggest ovarian cancer in line with the NICE guideline on [ovarian cancer](#).<sup>[4]</sup> [2008]

1.1.1.4 A diagnosis of IBS should be considered only if the person has abdominal pain or discomfort that is either relieved by defaecation or associated with altered

bowel frequency or stool form. This should be accompanied by at least two of the following four symptoms:

- altered stool passage (straining, urgency, incomplete evacuation)
- abdominal bloating (more common in women than men), distension, tension or hardness
- symptoms made worse by eating
- passage of mucus.

Other features such as lethargy, nausea, backache and bladder symptoms are common in people with IBS, and may be used to support the diagnosis. [2008]

## 1.1.2 Diagnostic tests

1.1.2.1 In people who meet the IBS diagnostic criteria, the following tests should be undertaken to exclude other diagnoses:

- full blood count (FBC)
- erythrocyte sedimentation rate (ESR) or plasma viscosity
- c-reactive protein (CRP)
- antibody testing for coeliac disease (endomysial antibodies [EMA] or tissue transglutaminase [TTG]). [2008]

1.1.2.2 The following tests are not necessary to confirm diagnosis in people who meet the IBS diagnostic criteria:

- ultrasound
- rigid/flexible sigmoidoscopy
- colonoscopy; barium enema
- thyroid function test
- faecal ova and parasite test
- faecal occult blood

- hydrogen breath test (for lactose intolerance and bacterial overgrowth). [2008]

## 1.2 *Clinical management of IBS*

### 1.2.1 Dietary and lifestyle advice

- 1.2.1.1 People with IBS should be given information that explains the importance of self-help in effectively managing their IBS. This should include information on general lifestyle, physical activity, diet and symptom-targeted medication. [2008]
- 1.2.1.2 Healthcare professionals should encourage people with IBS to identify and make the most of their available leisure time and to create relaxation time. [2008]
- 1.2.1.3 Healthcare professionals should assess the physical activity levels of people with IBS, ideally using the General Practice Physical Activity Questionnaire (GPPAQ; see appendix J of the full guideline). People with low activity levels should be given brief advice and counselling to encourage them to increase their activity levels. [2008]
- 1.2.1.4 Diet and nutrition should be assessed for people with IBS and the following general advice given.
- Have regular meals and take time to eat.
  - Avoid missing meals or leaving long gaps between eating.
  - Drink at least 8 cups of fluid per day, especially water or other non-caffeinated drinks, for example herbal teas.
  - Restrict tea and coffee to 3 cups per day.
  - Reduce intake of alcohol and fizzy drinks.
  - It may be helpful to limit intake of high-fibre food (such as wholemeal or high-fibre flour and breads, cereals high in bran, and whole grains such as brown rice).
  - Reduce intake of 'resistant starch' (starch that resists digestion in the small intestine and reaches the colon intact), which is often found in processed or re-cooked foods.

- Limit fresh fruit to 3 portions per day (a portion should be approximately 80 g).
- People with diarrhoea should avoid sorbitol, an artificial sweetener found in sugar-free sweets (including chewing gum) and drinks, and in some diabetic and slimming products.
- People with wind and bloating may find it helpful to eat oats (such as oat-based breakfast cereal or porridge) and linseeds (up to 1 tablespoon per day). [2008]

1.2.1.5 Healthcare professionals should review the fibre intake of people with IBS, adjusting (usually reducing) it while monitoring the effect on symptoms. People with IBS should be discouraged from eating insoluble fibre (for example, bran). If an increase in dietary fibre is advised, it should be soluble fibre such as ispaghula powder or foods high in soluble fibre (for example, oats). [2008]

1.2.1.6 People with IBS who choose to try probiotics should be advised to take the product for at least 4 weeks while monitoring the effect. Probiotics should be taken at the dose recommended by the manufacturer. [2008]

1.2.1.7 Healthcare professionals should discourage the use of aloe vera in the treatment of IBS. [2008]

1.2.1.8 If a person's IBS symptoms persist while following general lifestyle and dietary advice, offer advice on further dietary management. Such advice should:

- include single food avoidance and exclusion diets (for example, a low FODMAP [fermentable oligosaccharides, disaccharides, monosaccharides and polyols] diet)
- only be given by a healthcare professional with expertise in dietary management. [new 2015]

## 1.2.2 Pharmacological therapy

Decisions about pharmacological management should be based on the nature and severity of symptoms. The recommendations made below assume that the choice of single or combination medication is determined by the predominant symptom(s).

1.2.2.1 Healthcare professionals should consider prescribing antispasmodic agents for people with IBS. These should be taken as required, alongside dietary and lifestyle advice. [2008]

1.2.2.2 Laxatives should be considered for the treatment of constipation in people with IBS, but people should be discouraged from taking lactulose. [2008]

1.2.2.3 Consider linaclotide for people with IBS only if:

- optimal or maximum tolerated doses of previous laxatives from different classes have not helped and
- they have had constipation for at least 12 months.

Follow up people taking linaclotide after 3 months. [new 2015]

1.2.2.4 Loperamide should be the first choice of antimotility agent for diarrhoea in people with IBS. [2008]

1.2.2.5 People with IBS should be advised how to adjust their doses of laxative or antimotility agent according to the clinical response. The dose should be titrated according to stool consistency, with the aim of achieving a soft, well-formed stool (corresponding to Bristol Stool Form Scale type 4). [2008]

1.2.2.6 Consider tricyclic antidepressants (TCAs) as second-line treatment for people with IBS if laxatives, loperamide or antispasmodics have not helped. Start treatment at a low dose (5–10 mg equivalent of amitriptyline), taken once at night, and review regularly. Increase the dose if needed, but not usually beyond 30 mg.<sup>[6]</sup> [2015]

1.2.2.7 Consider selective serotonin reuptake inhibitors (SSRIs) for people with IBS only if TCAs are ineffective.<sup>[6]</sup>[2015]

1.2.2.8 Take into account the possible side effects when offering TCAs or SSRIs to people with IBS. Follow up people taking either of these drugs for the first time at low doses for the treatment of pain or discomfort in IBS after 4 weeks and then every 6–12 months.<sup>[6]</sup>[2015]

## 1.2.3 Psychological interventions

1.2.3.1 Referral for psychological interventions (cognitive behavioural therapy [CBT], hypnotherapy and/or psychological therapy) should be considered for people with IBS who do not respond to pharmacological treatments after 12 months



and who develop a continuing symptom profile (described as refractory IBS).  
[2008]

## 1.2.4 Complementary and alternative medicine (CAM)

1.2.4.1 The use of acupuncture should not be encouraged for the treatment of IBS.  
[2008]

1.2.4.2 The use of reflexology should not be encouraged for the treatment of IBS.  
[2008]

## 1.2.5 Follow-up

1.2.5.1 Follow-up should be agreed between the healthcare professional and the person with IBS, based on the response of the person's symptoms to interventions. This should form part of the annual patient review. The emergence of any 'red flag' symptoms during management and follow-up should prompt further investigation and/or referral to secondary care. [2008]

---

<sup>[4]</sup> See NICE's [referral guidelines for suspected cancer](#) for detailed referral criteria where cancer is suspected.

<sup>[5]</sup> This recommendation was updated in September 2012 in line with more recent guidance on the recognition and management of ovarian cancer in the NICE guideline on [ovarian cancer](#).

<sup>[6]</sup> At the time of publication (February 2015), TCAs and SSRIs did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Good practice in prescribing and managing medicines and devices](#) for further information.

## 2 Research recommendations

In 2008, the Guideline Development Group made the following recommendations for research, based on its review of evidence, to improve NICE guidance and patient care in the future.

As part of the 2015 update, the Committee made 3 additional research recommendations on the clinical and cost effectiveness of a low FODMAP diet, low-dose TCAs and SSRIs in primary care, and computerised CBT and mindfulness therapy. These can be found in the [addendum](#).

### 2.1 *Low-dose antidepressants*

Are low-dose TCAs, SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs) effective as first-line treatment for IBS, and which is the most effective and safe option?

#### **Why this is important**

Reviews have shown that TCAs and SSRIs have each been compared with placebo in the treatment of IBS, but not at low doses. In practice, TCAs are used at higher doses, and concordance with treatment is poor because of side effects. The Guideline Development Group clinicians believe that at low doses (5–10 mg equivalent of amitriptyline), TCAs could be the treatment of choice for IBS, but there is a lack of evidence to support this. A newer type of antidepressant, SNRIs, may also be useful in the treatment of IBS-associated pain. A large randomised trial is proposed, comparing an SSRI, a TCA and an SNRI with placebo. Participants should be adults with a positive diagnosis of IBS, stratified by type of IBS and randomised to treatments. The type of IBS is defined by the predominant bowel symptom: diarrhoea, constipation or alternating symptoms. The primary outcome should be global improvement in IBS symptoms. Health-related quality of life should also be measured, and adverse effects recorded. Study outcomes should be assessed 12, 26 and 52 weeks after the start of therapy.

### 2.2 *Psychological interventions*

Are the psychological interventions CBT, hypnotherapy and psychological therapy all equally effective in the management of IBS symptoms, either as first-line therapies in primary care, or in the treatment of people with IBS that is refractory to other treatments?

#### **Why this is important**

Reviews show some evidence of effect when comparing psychological interventions with a control group, with the greatest effect shown in people who have refractory IBS. Many trials are small in size. Certain psychological interventions – namely, CBT, hypnotherapy and psychological therapy – are thought to be useful in helping people with IBS to cope with their symptoms, but it is unclear at what stage these should be given, including whether they should be used as first-line therapies in primary care. A large randomised trial is proposed, comparing CBT, hypnotherapy and psychological therapy (in particular, psychodynamic interpersonal therapy). Participants should be adults with a positive diagnosis of IBS, and they should be stratified into those with and without refractory IBS and then randomised to treatments. The primary outcome should be global improvement in IBS symptoms. Health-related quality of life should also be measured, and adverse effects recorded. Study outcomes should be assessed 12, 26 and 52 weeks after the start of therapy.

### 2.3 *Refractory IBS*

What factors contribute to refractory IBS?

#### **Why this is important**

Most people with IBS experience symptoms that are relatively short-lived or that only trouble them on an intermittent basis. Some people, however, develop chronic and severe symptoms that are difficult to treat. There are relatively few prospective studies that have investigated this problem.

A large, prospective, population-based cohort study is proposed, which would evaluate people in the community with IBS symptoms according to measures of bowel symptomatology, physical symptom profile, psychological symptoms, childhood adversity, psychiatric history, social supports, quality of life and other relevant potential predictors. Participants would be re-evaluated 12 and 24 months later using similar measures. Baseline variables would be used to predict chronicity of symptoms, quality of life and healthcare utilisation at 12 and 24 months.

### 2.4 *Relaxation and biofeedback*

What is the effect of relaxation and biofeedback therapies on IBS symptoms and patient-related outcomes?

#### **Why this is important**

Reviews of biofeedback and relaxation therapies suggest a positive effect on the control of IBS symptoms, but evidence is limited and not sufficient to make recommendations. Patient representation in the Guideline Development Group supports this view, from a personal and anecdotal perspective.

Recent developments in computer-aided biofeedback methods merit investigation. A large randomised trial is proposed to compare relaxation therapy, computer-aided biofeedback therapy and attention control in primary care. Participants should be adults with a positive diagnosis of IBS, and they should be stratified into those with and without refractory IBS and then randomised to treatments. The primary outcome should be global improvement in IBS symptoms. Health-related quality of life should also be measured, and adverse effects recorded. Study outcomes should be assessed 12, 26 and 52 weeks after the start of therapy. Qualitative data should be generated relating to how people with IBS perceive their condition.

## 2.5 *Herbal medicines*

Are Chinese and non-Chinese herbal medicines safe and effective as first-line therapy in the treatment of IBS, and which is the most effective and safe option?

### **Why this is important**

Reviews of herbal medicines suggest a positive effect on the control of IBS symptoms, but evidence is limited and not sufficient to make recommendations (8 comparisons from the 6 trials provide heterogeneous data, which are very difficult to interpret). A large randomised placebo-controlled trial is proposed, comparing Chinese and non-Chinese herbal medicines (both single and multiple compounds) that are available in the UK as standard preparations. Participants should be adults with a positive diagnosis of IBS, and they should be stratified by type of IBS and then randomised to treatments. The primary outcome should be global improvement in IBS symptoms, with symptom scores recorded using a validated scale. Health-related quality of life should also be measured, and adverse events recorded. Study outcomes should be assessed 12, 26 and 52 weeks post-intervention.

## 3 Other information

### 3.1 *Scope and how this guideline was developed*

The [scope](#) for the 2008 guideline covers the recommendations labelled [2008]. The recommendations labelled [2015] have been produced during the update.

The guideline covers adults (18 years and older) who present to primary care with symptoms suggestive of IBS, and the care that is provided by primary healthcare professionals, indicating where secondary care referral is appropriate. It does not cover:

- people with other gastrointestinal disorders such as non-ulcer dyspepsia or coeliac disease
- children and young people under 18 years
- inflammatory bowel disease.

#### How this guideline was developed

The 2008 guideline was developed by the National Collaborating Centre for Nursing and Supportive Care based at the Royal College of Nursing. The Collaborating Centre worked with a Guideline Development Group, comprising healthcare professionals (including consultants, GPs and nurses), patients and carers, and technical staff, which reviewed the evidence and drafted the recommendations. The recommendations were finalised after public consultation. NICE's Clinical Guidelines Update Programme updated this guideline in 2015. This guideline was updated using a Committee of healthcare professionals, methodologists and lay members from a range of disciplines and localities, as well as topic experts.

The methods and processes for developing NICE clinical guidelines can be found [here](#).

### 3.2 *Related NICE guidance*

Details are correct at the time of publication of the guideline (February 2015). Further information is available on the [NICE website](#).

## Published

### *General*

- [Patient experience in adult NHS services](#) (2012) NICE guideline CG138

- [Medicines adherence \(2009\) NICE guideline CG76](#)

### **Condition-specific**

- [Irritable bowel syndrome with constipation in adults: linaclotide \(2013\) NICE advice ESNM16](#)
- [Bile acid malabsorption: colesevelam \(2013\) NICE advice ESUOM22](#)
- [Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel \(2013\) NICE diagnostics guidance 11](#)
- [Physical activity: brief advice for adults in primary care \(2013\) NICE guideline PH44](#)
- [SeHCAT \(tauroselcholic \[75 selenium\] acid\) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome \(IBS-D\) or Crohn's disease without ileal resection \(2012\) NICE diagnostics guidance 7](#)
- [Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas \(2011\) NICE guideline CG118](#)
- [Prucalopride for the treatment of chronic constipation in women \(2010\) NICE technology appraisal guidance 211](#)
- [Depression in adults \(2009\) NICE guideline CG90](#)
- [Faecal incontinence \(2007\) NICE guideline CG49](#)
- [Physical activity \(2006\) NICE guideline PH2](#)
- [Referral guidelines for suspected cancer \(2005\) NICE guideline CG27](#)

## 4 Committee members and NICE staff

### 4.1 *Committee members*

Committee members for the 2015 update are listed on the [NICE website](#). For the composition of the previous Guideline Development Group, see the [full guideline](#).

### 4.2 *Clinical Guidelines Update Team*

**Phil Alderson**

Clinical Adviser

**Emma Banks**

Co-ordinator

**Sara Buckner**

Technical Analyst

**Paul Crosland**

Health Economist

**Nicole Elliott**

Associate Director

**Cheryl Hookway**

Technical Analyst

**Jenny Kendrick**

Information Scientist

**Susannah Moon**

Programme Manager

**Rebecca Parsons**

Project Manager

**Charlotte Purves**

Administrator

**Robby Richey (until September 2014)**

Technical Analyst

**Toni Tan**

Technical Adviser

### **4.3 NICE project team**

**Mark Baker**

Clinical Lead

**Christine Carson**

Guideline Lead

**Jessica Fielding (from January 2015)**

Public Involvement Adviser

**Barbara Meredith (until September 2014)**

Public Involvement Adviser

**Bhash Naidoo**

Technical Lead (Health Economics)

**Katie Prickett**

Editor

**Beth Shaw**

Technical Lead

**Louise Shires**

Guideline Commissioning Manager

**Jennifer Wells**

Guideline Coordinator

**Erin Whittingham (from September 2014)**

Public Involvement Adviser



#### 4.4 *Declarations of interests*

The following members of the Committee made declarations of interest. All other members of the Committee stated that they had no interests to declare.

Committee member	Interest declared	Type of interest	Decision taken
Damien Longson	Family member employee of NICE.	Personal family non-specific	Declare and participate
Damien Longson	Director of Research and Innovation, Manchester Mental Health and Social Care NHS Trust.	Personal non-specific pecuniary	Declare and participate
Catherine Briggs	Husband is a Consultant Anaesthetist at the University Hospital of South Manchester.	Personal family non-specific	Declare and participate
Catherine Briggs	Member of the Royal College of Surgeons, the Royal College of General Practitioners, the Faculty of Sexual and Reproductive Health and the British Medical Association.	Personal non-specific pecuniary	Declare and participate
John Cape	Trustee of the Anna Freud Centre, a child and family mental health charity which applies for and receives grants from the Department of Health and the National Institute for Health Research.	Personal non-specific non-pecuniary	Declare and participate
John Cape	Member of British Psychological Society and British Association for Behaviour and Cognitive Psychotherapists who seek to influence policy towards psychology and psychological therapies.	Personal non-specific non-pecuniary	Declare and participate

Alun Davies	Research grant funding – commercial: Vascular Insights, Acergy Ltd, Firstkind, Laboratoires Urgo, Sapheon Inc. (terminated 2013). All administered by Imperial College London as Sponsor and Professor Davies as Chief Investigator.	Personal non-specific pecuniary	Declare and participate
Alun Davies	Research grant funding – non-commercial: National Institute for Health Research, British Heart Foundation, Royal College of Surgeons, Circulation Foundation, European Venous Forum.	Personal non-specific pecuniary	Declare and participate
Alun Davies	Non-commercial: Attendance at numerous national and international meetings as an invited guest to lecture where the organising groups receive funding from numerous sources including device and pharmaceutical manufacturers. Organising groups pay expenses and occasionally honoraria – the exact source of funding is often not known.	Personal non-specific pecuniary	Declare and participate
Alun Davies	Non-commercial: Received travel expenses to attend the Veith Meeting, New York, November 2013 to give lectures by Vascutek.	Personal non-specific pecuniary	Declare and participate
Alison Eastwood	Member of an independent academic team at Centre for Review and Dissemination, University of York commissioned by NICE through National Institute for Health Research to undertake technology assessment reviews.	Non-personal non-specific pecuniary	Declare and participate
Sarah Fishburn	Organises workshops for physiotherapists treating pelvic girdle pain. Paid for this work.	Personal non-specific pecuniary	Declare and participate

Sarah Fishburn	Receives payment and expenses from the Nursing and Midwifery Council as a lay panellist of the Fitness to Practise Investigating Committee.	Personal non-specific pecuniary	Declare and participate
Sarah Fishburn	Lay reviewer with the Local Supervising Authority auditing supervision of midwives – receives payment and expenses for this work.	Personal non-specific pecuniary	Declare and participate
Sarah Fishburn	Lay reviewer for the National Institute for Health Research; has reviewed a number of research proposals being considered for funding. Paid for carrying out these reviews.	Personal non-specific pecuniary	Declare and participate
Sarah Fishburn	Chair of the Pelvic Partnership, a support group for women with pregnancy-related pelvic girdle pain. This is a voluntary position.	Personal non-specific pecuniary	Declare and participate
Sarah Fishburn	Trained as a chartered physiotherapist and qualified in 1988 but has not been in clinical practice since 1997. Remains a non-practicing member of the Chartered Society of Physiotherapy.	Personal non-specific pecuniary	Declare and participate
Sarah Fishburn	Recently appointed by Mott MacDonald to carry out reviews as a lay reviewer on behalf to the Nursing and Midwifery Council of local supervising authorities and universities providing courses for nurses and midwives. This is paid work.	Personal non-specific pecuniary	Declare and participate
Jim Gray	Receives income for work as Deputy Editor/ Editor-in-Chief, Journal of Hospital Infection.	Personal non-specific non-pecuniary	Declare and participate
Nuala Lucas (until December 2014)	Member, Obstetric Anaesthetists' Association Executive Committee.	Personal non-specific non-pecuniary	Declare and participate

Nuala Lucas (until December 2014)	Member, NICE Intrapartum care Guideline Development Group.	Personal non-specific non-pecuniary	Declare and participate
Nuala Lucas (until December 2014)	Member, Editorial Board, International Journal of Obstetric Anaesthesia.	Personal non-specific non-pecuniary	Declare and participate
Kath Nuttall	None		No action
Tilly Pillay	None		No action
Nick Screaton	Attended Thorax meeting – travel expenses paid.	None specific personal pecuniary	No action
Nick Screaton	Senior Editor, British Journal of Radiology Specialised Imaging.	Personal non-specific non-pecuniary	Declare and participate
Nick Screaton	Advisory Editor, Clinical Radiology.	Personal non-specific non-pecuniary	Declare and participate
Nick Screaton	Chair, East of England British Institute of Radiology.	Personal non-specific non-pecuniary	Declare and participate
Nick Screaton	British Thoracic Society Bronchiectasis Guidelines Group member.	Personal non-specific non-pecuniary	Declare and participate
Nick Screaton	Director, Cambridge Clinical Imaging.	Personal non-specific non-pecuniary	Declare and participate
Nick Screaton	Clinical Commissioning Group stakeholder member.	Personal non-specific non-pecuniary	Declare and participate
Lindsay Smith	None		No action

Philippa Williams	None		No action
Sophie Wilne	Recipient of NHS Innovation Challenge Award for clinical awareness campaign to reduce delays in diagnosis of brain tumours in children and young adults. Award will be used to develop the campaign.	Personal non-specific non-pecuniary	Declare and participate
Sophie Wilne	Co-investigator for Research for Patient Benefit grant to undertake systematic reviews in childhood brain tumours.	Personal non-specific non-pecuniary	Declare and participate
Sophie Wilne	Co-investigator for grant awards from charity to evaluate impact of brain tumour awareness campaign.	Personal non-specific non-pecuniary	Declare and participate
Sophie Wilne	Speaker at conferences to talk about tuberous sclerosis – invited by Novartis – travel expenses only.	Personal non-specific non-pecuniary	Declare and participate
Sophie Wilne	Presented at educational meetings sponsored by drug companies – not paid for educational events.	Personal non-specific non-pecuniary	Declare and participate
Topic-specific member	Interest declared	Type of interest	Decision
Mark Follows	None		No action
Elsbeth Guthrie	None		No action
Yvonne McKenzie	Voluntary role – Clinical Lead in IBS for the Gastroenterology Specialist Group of the British Dietetic Association. Role has received honoraria.	Personal non-pecuniary	Declare and participate

Yvonne McKenzie	Chair of team of 9 Gastroenterology Specialist Group dietitians, systematically reviewing the British Dietetic Association's 2010 guidelines on the dietary management of IBS. This review will be transferred to the Practice-based Evidence in Nutrition (PEN) database, a global dietetic resource for dietitians. Small amount of funding by PEN and honorarium will be received. May gain funding to cover some personal time for writing guideline document. Travel, meeting refreshments and telephone expenses paid by the Gastroenterology Specialist Group.	Personal non-pecuniary	Declare and participate
Yvonne McKenzie	Developing dietetic outcomes for IBS management. Travel, meeting refreshments and telephone expenses paid by the Gastroenterology Specialist Group.	Personal non-pecuniary	Declare and participate
Yvonne McKenzie	Developing an IBS key fact sheet that will provide guidance on the value of the role of the dietitian in IBS management, for GPs, therapy management, Clinical Commissioning Groups.	Personal non-pecuniary	Declare and participate
Yvonne McKenzie	Wrote a chapter on IBS for the Manual of Dietetic Practice. Published in June 2014 5 <sup>th</sup> Edition.	Personal non-pecuniary	Declare and participate
Yvonne McKenzie	Presentation to be filmed 'Can probiotics help with IBS-type gut problems?' Yakult healthcare professionals study day at Royal College of Physicians. Stand alone paid educational work.	Personal non-pecuniary	Declare and participate
Yvonne McKenzie	Part of editorial panel for Dietetics Today, the British Dietetic Association's official magazine.	Personal non-pecuniary	Declare and participate

Yvonne McKenzie	Write articles on IBS for clinical dietetic practice and continuing professional development purposes (on FODMAPS – issued January 2013 and further article due October 2014).	Personal non-pecuniary	Declare and participate
Yvonne McKenzie	Planning to write further article to encourage dietitians who are British Dietetic Association members to have stronger leadership roles in gastroenterology, may include sections on supporting dietetic-led IBS management in the community.	Personal non-pecuniary	Declare and participate
Marion Saunders	Patient member on the Psychological Therapies/Gastrointestinal advisory group at BUPA.	Personal non-pecuniary	No action
Simon Smale	Chief Medical Officer associated with equity share in Healthbox360.me, a technology start up aiming to deliver an integrated multi professional digital health platform providing tools for behaviour and lifestyle changes for those at risk of and with specific chronic diseases (diabetes and cardiovascular disease at present). Currently awaiting Care Quality Commission registration.	Personal financial non-specific	Declare and participate
Simon Smale	Sponsorship of meeting attendance (United European Gastroenterology Week in Vienna) by Tillotts Pharma.	Personal financial non-specific	Declare and participate

<p>Peter Whorwell (non-voting expert)</p>	<p>Advisory board member for Almirall.</p>	<p>Specific personal non-pecuniary</p>	<p>Excluded from recommendation drafting part of Committee meeting. Required to leave for the laxatives question as Almirall are involved with linaclotide.</p>
<p>Peter Whorwell (non-voting expert)</p>	<p>Research grants from Almirall, Danone, Salix (published on hypnotherapy, acupuncture, probiotics).</p>	<p>Specific personal non-pecuniary</p>	<p>Required to leave for the laxatives question as Almirall are involved with linaclotide.</p>



## About this guideline

NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions.

NICE guidelines are developed in accordance with a [scope](#) that defines what the guideline will and will not cover.

The original guideline (published in 2008) was developed by the National Collaborating Centre for Nursing and Supportive Care, based at the Royal College of Nursing. The Collaborating Centre worked with a Guideline Development Group, comprising healthcare professionals (including consultants, GPs and nurses), patients and carers, and technical staff, which reviewed the evidence and drafted the recommendations. NICE's Clinical Guidelines Update Programme updated this guideline in 2015. This guideline was updated using a Committee of healthcare professionals, methodologists and lay members from a range of disciplines and localities, as well as topic experts.

The recommendations were finalised after public consultation.

The methods and processes for developing NICE clinical guidelines can be found [here](#).

NICE produces guidance, standards and information on commissioning and providing high-quality healthcare, social care, and public health services. We have agreements to provide certain NICE services to Wales, Scotland and Northern Ireland. Decisions on how NICE guidance and other products apply in those countries are made by ministers in the Welsh government, Scottish government, and Northern Ireland Executive. NICE guidance or other products may include references to organisations or people responsible for commissioning or providing care that may be relevant only to England.

## *Update information*

New recommendations on dietary and lifestyle advice and pharmacological therapy have been added to the [clinical management of IBS](#) section.

Recommendations are marked as [new 2015], [2015] and [2008]:

- [new 2015] indicates that the evidence has been reviewed and the recommendation has been added or updated
- [2015] indicates that the evidence has been reviewed but no change has been made to the recommended action
- [2008] indicates that the evidence has not been reviewed since 2008.

Please note that in the 2015 update, a new recommendation 1.2.2.3 has been added. Therefore, the recommendations that were numbered as 1.2.2.3 to 1.2.2.7 in the 2008 guideline have been renumbered as recommendations 1.2.2.4 to 1.2.2.8 in the 2015 update. The 2008 recommendation numbers have been retained in the [full guideline](#).

## *Strength of recommendations*

Some recommendations can be made with more certainty than others. The Committee makes a recommendation based on the trade-off between the benefits and harms of an intervention, taking into account the quality of the underpinning evidence. For some interventions, the Committee is confident that, given the information it has looked at, most patients would choose the intervention. The wording used in the recommendations in this guideline denotes the certainty with which the recommendation is made (the strength of the recommendation).

For all recommendations, NICE expects that there is discussion with the patient about the risks and benefits of the interventions, and their values and preferences. This discussion aims to help them to reach a fully informed decision (see also [patient-centred care](#)).

## **Interventions that must (or must not) be used**

We usually use 'must' or 'must not' only if there is a legal duty to apply the recommendation. Occasionally we use 'must' (or 'must not') if the consequences of not following the recommendation could be extremely serious or potentially life threatening.

## **Interventions that should (or should not) be used – a 'strong' recommendation**

We use 'offer' (and similar words such as 'refer' or 'advise') when we are confident that, for the vast majority of patients, an intervention will do more good than harm, and be cost effective. We use similar forms of words (for example, 'Do not offer...') when we are confident that an intervention will not be of benefit for most patients.

## Interventions that could be used

We use 'consider' when we are confident that an intervention will do more good than harm for most patients, and be cost effective, but other options may be similarly cost effective. The choice of intervention, and whether or not to have the intervention at all, is more likely to depend on the patient's values and preferences than for a strong recommendation, and so the healthcare professional should spend more time considering and discussing the options with the patient.

## Recommendation wording in guideline updates

NICE began using this approach to denote the strength of recommendations in guidelines that started development after publication of the 2009 version of 'The guidelines manual' (January 2009). This does not apply to any recommendations ending [2008] (see 'Update information' above for details about how recommendations are labelled). In particular, for recommendations labelled [2008] the word 'consider' may not necessarily be used to denote the strength of the recommendation.

## *Other versions of this guideline*

The full guideline, [Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care](#), contains details of the methods and evidence used to develop the guideline. It is published by the National Collaborating Centre for Nursing and Supportive Care.

The [addendum](#) to the full guideline contains details of the methods and evidence used to develop the updated recommendations (labelled [2015] and [new 2015]).

The recommendations from this guideline have been incorporated into a [NICE pathway](#).

We have produced [information for the public](#) about this guideline.

## *Implementation*

[Implementation tools and resources](#) to help you put the guideline into practice are also available.

## *Your responsibility*

This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual

responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summaries of product characteristics of any drugs.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

## *Copyright*

© National Institute for Health and Care Excellence 2015. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

ISBN 978-1-4731-1024-3

## *Accreditation*

